For instance, B-cell-depleting therapies using the monoclonal antibodies rituximab and the B-lymphocyte stimulator (BLyS) inhibitor belimumab have been beneficial in a specific subpopulation of lupus patients [7,8]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.